ArticlePlacenta2026
Placental gene expression signatures based on maternal parity.
Article in Placenta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Clinical Factors and Parity-Specific Models with Molecular Biomarkers to Better Predict the Risk of Preterm Birth in Asymptomatic Women.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionNulliparity is associated with adverse pregnancy outcomes including preeclampsia, preterm birth, lower birth weight and stillbirth although mechanisms are unclear. Placental gene expression differences, which also vary by fetal sex, may drive altered placental function and explain pregnancy outcome differences between nulliparous and multiparous women. This study aims to identify placental gene expression differences based on parity and examine their relationship with birth weight.
methodsRNA sequencing was performed on placental samples collected at delivery as part of the NICHD Fetal Growth Studies. Differentially expressed genes between placentas of nulliparous (n = 34) and multiparous (n = 41) participants were determined in the full cohort and stratified by fetal sex. Weighted gene co-expression network analysis was performed to identify co-expression modules associated with parity. Correlation of differentially expressed genes and co-expression modules with birth weight was assessed.
resultsFive differentially expressed genes were identified (FDR p < 0.05) including DDX5 (higher expression in multiparas in full cohort), ANKRD33 and SLITRK6 (higher in multiparas in female sub-cohort), and IL1B and MTCO1P40 (higher in nulliparas in female sub-cohort). Two gene co-expression modules, "Grey60" and "Tan", were negatively associated with multiparity. The DDX5 and ILB1 genes, and the "Grey60" module were significantly correlated with birth weight within the parity group that exhibited lower expression. Genes in the two co-expression modules were enriched for pathways related to immune response, cardiovascular and reproductive system development, and cancer. DISCUSSION: Placental gene expression differences between nulliparas and multiparas may in part underlie neonatal outcomes that differ by parity and fetal sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.